Charles River Laboratories is moving forward with two planned acquisitions to strengthen its business operations. The company has signed an agreement to acquire K.F. (Cambodia) Ltd., a key supplier of non-human primates (NHPs) for its Discovery and Safety Assessment segment. This acquisition is expected to enhance supply chain security, provide significant cost savings, and improve operating margins. Additionally, Charles River Laboratories has exercised its option to acquire the remaining 79% equity stake in PathoQuest SAS, a Paris-based provider of next generation sequencing solutions for biopharmaceutical manufacturing quality-control testing. The PathoQuest acquisition aims to bolster Charles River’s biologics testing capabilities with innovative, rapid in vitro testing methods that support the replacement of animal use in viral safety workflows and accelerate clients’ quality-control timelines.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Charles River Laboratories International Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260112549794) on January 12, 2026, and is solely responsible for the information contained therein.